{"id":"lenvatinib-capsules","safety":{"commonSideEffects":[{"rate":"63","effect":"Hypertension"},{"rate":"47","effect":"Diarrhea"},{"rate":"46","effect":"Fatigue"},{"rate":"34","effect":"Decreased appetite"},{"rate":"32","effect":"Nausea"},{"rate":"26","effect":"Weight loss"},{"rate":"25","effect":"Proteinuria"},{"rate":"18","effect":"Vomiting"},{"rate":"15","effect":"Palmar-plantar erythrodysesthesia"}]},"_chembl":{"chemblId":"CHEMBL1289601","moleculeType":"Small molecule","molecularWeight":"426.86"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenvatinib inhibits multiple receptor tyrosine kinases including fibroblast growth factor receptors (FGFR1-4), vascular endothelial growth factor receptors (VEGFR1-3), RET, KIT, and PDGFR-alpha. By blocking these pathways, it suppresses tumor neovascularization and directly inhibits cancer cell proliferation. This multi-kinase approach is particularly effective in cancers dependent on FGF and VEGF signaling.","oneSentence":"Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and other kinases to inhibit tumor angiogenesis and growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:35.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Radioiodine-refractory differentiated thyroid cancer"},{"name":"Unresectable hepatocellular carcinoma"},{"name":"Advanced renal cell carcinoma (in combination with pembrolizumab)"},{"name":"Endometrial carcinoma (in combination with pembrolizumab)"}]},"trialDetails":[{"nctId":"NCT04199104","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-05","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":511},{"nctId":"NCT06858813","phase":"PHASE1","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-04-14","conditions":"Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer","enrollment":232},{"nctId":"NCT04008797","phase":"PHASE1, PHASE2","title":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2019-07-11","conditions":"Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular","enrollment":301},{"nctId":"NCT06036836","phase":"PHASE2","title":"Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-09-29","conditions":"Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer","enrollment":163},{"nctId":"NCT03486873","phase":"PHASE3","title":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-08-21","conditions":"Solid Tumors, Hematologic Malignancies","enrollment":3500},{"nctId":"NCT05523323","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-10-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":112},{"nctId":"NCT07463248","phase":"PHASE2","title":"PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Wang Xin","startDate":"2026-03-05","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":64},{"nctId":"NCT05824481","phase":"PHASE2","title":"Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-08","conditions":"Endometrial Cancer, Endometrial Adenocarcinoma","enrollment":32},{"nctId":"NCT05824468","phase":"PHASE2","title":"Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-10","conditions":"Cervical Cancer, Cervical Carcinoma","enrollment":30},{"nctId":"NCT03573960","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Eisai Pharmaceuticals India Pvt. Ltd","startDate":"2018-04-01","conditions":"Thyroid Neoplasms","enrollment":50},{"nctId":"NCT04586231","phase":"PHASE3","title":"A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-25","conditions":"Carcinoma, Renal Cell","enrollment":747},{"nctId":"NCT05603910","phase":"PHASE1","title":"Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma","status":"RECRUITING","sponsor":"Aaron Wolfson","startDate":"2023-04-15","conditions":"Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma","enrollment":18},{"nctId":"NCT03829332","phase":"PHASE3","title":"Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-13","conditions":"Non-small Cell Lung Cancer","enrollment":623},{"nctId":"NCT04710628","phase":"PHASE2","title":"Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents","status":"COMPLETED","sponsor":"MedSIR","startDate":"2021-09-21","conditions":"Metastatic Thymic Carcinoma, Thymoma Type B3","enrollment":43},{"nctId":"NCT04039607","phase":"PHASE3","title":"A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-09-30","conditions":"Hepatocellular Carcinoma","enrollment":732},{"nctId":"NCT05775159","phase":"PHASE2","title":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-04-24","conditions":"Hepatocellular Carcinoma, Biliary Tract Cancer","enrollment":294},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT04626479","phase":"PHASE1, PHASE2","title":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-16","conditions":"Carcinoma, Renal Cell","enrollment":400},{"nctId":"NCT03820986","phase":"PHASE3","title":"Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-12","conditions":"Malignant Melanoma","enrollment":674},{"nctId":"NCT03898180","phase":"PHASE3","title":"Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-06","conditions":"Urothelial Carcinoma","enrollment":505},{"nctId":"NCT04776148","phase":"PHASE3","title":"Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-03-29","conditions":"Colorectal Neoplasms","enrollment":563},{"nctId":"NCT03829319","phase":"PHASE3","title":"Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-25","conditions":"Nonsquamous Non-small Cell Lung Cancer","enrollment":761},{"nctId":"NCT03884101","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-04-11","conditions":"Endometrial Neoplasms","enrollment":842},{"nctId":"NCT04784247","phase":"PHASE2","title":"Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-03-18","conditions":"Advanced Sarcoma","enrollment":52},{"nctId":"NCT05273554","phase":"PHASE1","title":"A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-08-31","conditions":"Tumor, Adenocarcinoma","enrollment":15},{"nctId":"NCT04889118","phase":"PHASE3","title":"Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-14","conditions":"Malignant Melanoma","enrollment":131},{"nctId":"NCT07290894","phase":"PHASE2","title":"Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-12","conditions":"Vulva Cancer","enrollment":80},{"nctId":"NCT05030506","phase":"PHASE1","title":"A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-10-13","conditions":"Renal Cell Carcinoma","enrollment":45},{"nctId":"NCT05342636","phase":"PHASE1, PHASE2","title":"A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-27","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":90},{"nctId":"NCT04246177","phase":"PHASE3","title":"Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-22","conditions":"Carcinoma, Hepatocellular","enrollment":480},{"nctId":"NCT05296512","phase":"PHASE2","title":"Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elizabeth K. Lee MD","startDate":"2022-09-23","conditions":"Ovarian Clear Cell Carcinoma, Gynecologic Cancer","enrollment":30},{"nctId":"NCT04949256","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-07-28","conditions":"Metastatic Esophageal Squamous Cell Carcinoma","enrollment":864},{"nctId":"NCT07282509","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-12-23","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":116},{"nctId":"NCT05106127","phase":"PHASE2","title":"Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem","status":"NOT_YET_RECRUITING","sponsor":"Evergreen Therapeutics, Inc.","startDate":"2026-08","conditions":"Advanced Endometrial Cancer","enrollment":28},{"nctId":"NCT05077215","phase":"PHASE3","title":"Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Evergreen Therapeutics, Inc.","startDate":"2026-12","conditions":"Advanced Endometrial Cancer","enrollment":450},{"nctId":"NCT04428151","phase":"PHASE2","title":"Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":408},{"nctId":"NCT04865289","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-10-22","conditions":"Endometrial Neoplasms","enrollment":130},{"nctId":"NCT06673628","phase":"PHASE2","title":"Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients","status":"RECRUITING","sponsor":"National Cancer Center, Japan","startDate":"2024-12-01","conditions":"Angiosarcoma of Skin, Angiosarcoma Metastatic","enrollment":38},{"nctId":"NCT03797326","phase":"PHASE2","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-02-12","conditions":"Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer","enrollment":611},{"nctId":"NCT05899049","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-27","conditions":"Carcinoma, Renal Cell","enrollment":249},{"nctId":"NCT04700072","phase":"PHASE1, PHASE2","title":"Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-05-03","conditions":"Melanoma","enrollment":56},{"nctId":"NCT05091346","phase":"PHASE1, PHASE2","title":"A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2021-10-27","conditions":"Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms","enrollment":89},{"nctId":"NCT04209660","phase":"PHASE2","title":"Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-06-02","conditions":"Adenoid Cystic Carcinoma, Salivary Gland Cancer","enrollment":64},{"nctId":"NCT04865887","phase":"PHASE2","title":"Pembrolizumab and Lenvatinib in Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2022-10-07","conditions":"Cervical Cancer, Metastatic Cervical Cancer","enrollment":35},{"nctId":"NCT04447755","phase":"PHASE2","title":"A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-30","conditions":"Relapsed or Refractory Solid Tumors","enrollment":127},{"nctId":"NCT06030037","phase":"PHASE2","title":"Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma","status":"WITHDRAWN","sponsor":"Diwakar Davar","startDate":"2025-03-11","conditions":"PD-1 Refractory Advanced Melanoma","enrollment":""},{"nctId":"NCT07188311","phase":"NA","title":"Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-10","conditions":"Hepatoblastoma, Pediatric Cancer","enrollment":24},{"nctId":"NCT07184424","phase":"NA","title":"Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC","status":"COMPLETED","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2023-05-24","conditions":"HCC - Hepatocellular Carcinoma","enrollment":24},{"nctId":"NCT04716933","phase":"PHASE3","title":"Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-11-05","conditions":"Nonsquamous Non-small Cell Lung Cancer","enrollment":201},{"nctId":"NCT04305054","phase":"PHASE1, PHASE2","title":"Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-01","conditions":"Melanoma","enrollment":315},{"nctId":"NCT04305041","phase":"PHASE1, PHASE2","title":"Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-06-26","conditions":"Melanoma","enrollment":100},{"nctId":"NCT03976375","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-26","conditions":"Metastatic Non-Small Cell Lung Cancer","enrollment":422},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT05822752","phase":"PHASE2","title":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-09-21","conditions":"Hepatocellular Carcinoma","enrollment":130},{"nctId":"NCT07096609","phase":"PHASE1, PHASE2","title":"Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-09-08","conditions":"GIST","enrollment":48},{"nctId":"NCT04626518","phase":"PHASE1, PHASE2","title":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-17","conditions":"Carcinoma, Renal Cell","enrollment":370},{"nctId":"NCT02678780","phase":"PHASE2","title":"Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2015-10","conditions":"Neuroendocrine Tumors","enrollment":123},{"nctId":"NCT05101629","phase":"PHASE2","title":"Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2022-05-11","conditions":"Hepatocellular Carcinoma","enrollment":32},{"nctId":"NCT04924101","phase":"PHASE2","title":"Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-07-15","conditions":"Small Cell Lung Cancer","enrollment":126},{"nctId":"NCT03781934","phase":"PHASE1, PHASE2","title":"A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations","status":"COMPLETED","sponsor":"Medivir","startDate":"2018-09-05","conditions":"Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Metastases","enrollment":53},{"nctId":"NCT03516981","phase":"PHASE2","title":"A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-01","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":245},{"nctId":"NCT05774899","phase":"PHASE1, PHASE2","title":"CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC","status":"RECRUITING","sponsor":"Glenn J. Hanna","startDate":"2023-06-01","conditions":"Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma","enrollment":32},{"nctId":"NCT05660213","phase":"","title":"A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-08","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":750},{"nctId":"NCT03324373","phase":"PHASE1","title":"Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)","status":"COMPLETED","sponsor":"Yousef Zakharia","startDate":"2019-03-20","conditions":"Renal Cell Carcinoma","enrollment":11},{"nctId":"NCT05342194","phase":"PHASE3","title":"Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-06-19","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":480},{"nctId":"NCT05384015","phase":"PHASE2","title":"Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2022-11-07","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":46},{"nctId":"NCT04976634","phase":"PHASE2","title":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-08-18","conditions":"Neoplasm Malignant","enrollment":730},{"nctId":"NCT04676412","phase":"PHASE3","title":"Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-10-23","conditions":"Non-small Cell Lung Cancer","enrollment":107},{"nctId":"NCT03173560","phase":"PHASE2","title":"Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-08-17","conditions":"Renal Cell Carcinoma","enrollment":343},{"nctId":"NCT06896396","phase":"PHASE1, PHASE2","title":"Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhiyong Huang","startDate":"2025-04-01","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT04401800","phase":"PHASE2","title":"Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-09-04","conditions":"Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma","enrollment":64},{"nctId":"NCT06032845","phase":"PHASE2","title":"Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-09-13","conditions":"Solid Tumor, Adult","enrollment":25},{"nctId":"NCT06746961","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2025-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":49},{"nctId":"NCT06739395","phase":"PHASE2","title":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2024-11-01","conditions":"Solid Tumor, Precision Medicine","enrollment":300},{"nctId":"NCT05789667","phase":"","title":"Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer","status":"RECRUITING","sponsor":"Regina Elena Cancer Institute","startDate":"2020-05-27","conditions":"Differentiated Thyroid Cancer, Gender","enrollment":50},{"nctId":"NCT04736706","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-04-14","conditions":"Carcinoma, Renal Cell","enrollment":1653},{"nctId":"NCT04287829","phase":"PHASE2","title":"Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2021-03-01","conditions":"Mesotheliomas Pleural","enrollment":58},{"nctId":"NCT06643533","phase":"","title":"Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004)","status":"NOT_YET_RECRUITING","sponsor":"Fujian Provincial Hospital","startDate":"2025-01-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":15},{"nctId":"NCT05258279","phase":"PHASE2","title":"Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Juntendo University","startDate":"2022-07-01","conditions":"Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation","enrollment":30},{"nctId":"NCT06563934","phase":"PHASE2","title":"Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs)","status":"NOT_YET_RECRUITING","sponsor":"Xu Yong, MD","startDate":"2024-08-30","conditions":"Liver Cancer","enrollment":70},{"nctId":"NCT04154189","phase":"PHASE2","title":"A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2020-03-23","conditions":"Osteosarcoma","enrollment":81},{"nctId":"NCT04763408","phase":"","title":"A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2021-04-09","conditions":"Carcinoma, Hepatocellular","enrollment":335},{"nctId":"NCT06499610","phase":"PHASE4","title":"Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2024-07-15","conditions":"Gastric Cancer","enrollment":44},{"nctId":"NCT06409637","phase":"PHASE1, PHASE2","title":"FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-01-01","conditions":"Liver Cancer, Liver Transplant","enrollment":62},{"nctId":"NCT06406634","phase":"PHASE2","title":"Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2024-05-15","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT06389500","phase":"PHASE2","title":"HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-05-01","conditions":"Biliary Tract Cancer","enrollment":30},{"nctId":"NCT06320301","phase":"PHASE2","title":"Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-04-01","conditions":"Biliary Tract Cancer, Gemox Chemotherapy","enrollment":43},{"nctId":"NCT03006926","phase":"PHASE1","title":"A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2017-02-13","conditions":"Hepatocellular Carcinoma","enrollment":104},{"nctId":"NCT03867370","phase":"PHASE1, PHASE2","title":"Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2019-04-26","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT04297254","phase":"PHASE4","title":"A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC","status":"COMPLETED","sponsor":"Eisai Pharmaceuticals India Pvt. Ltd","startDate":"2021-02-04","conditions":"Carcinoma, Hepatocellular","enrollment":50},{"nctId":"NCT05250843","phase":"PHASE2, PHASE3","title":"TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-05-30","conditions":"Hepatocellular Carcinoma","enrollment":90},{"nctId":"NCT04858867","phase":"NA","title":"Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2022-01-10","conditions":"Differentiated Thyroid Cancer","enrollment":12},{"nctId":"NCT03245151","phase":"PHASE1, PHASE2","title":"Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-11-16","conditions":"Recurrent and Refractory Solid Tumors","enrollment":64},{"nctId":"NCT05617859","phase":"PHASE2","title":"Lenvatinib for Advanced Bone and Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2023-04-30","conditions":"Effectiveness, Sexuality","enrollment":60},{"nctId":"NCT05823987","phase":"PHASE2","title":"Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-05-16","conditions":"Advanced Biliary Tract Cancer","enrollment":25},{"nctId":"NCT05893056","phase":"PHASE2","title":"Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-06-16","conditions":"Gastric Cancer Metastatic to Liver","enrollment":25},{"nctId":"NCT05897268","phase":"PHASE2","title":"Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-06-20","conditions":"Hepatocellular Carcinoma","enrollment":25},{"nctId":"NCT01525394","phase":"PHASE1","title":"A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2010-12","conditions":"Refractory Solid Tumors, Lymphomas","enrollment":52},{"nctId":"NCT01321554","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-03-17","conditions":"Thyroid Cancer","enrollment":392},{"nctId":"NCT05903456","phase":"PHASE2","title":"Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-07","conditions":"Hepatocellular Carcinoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LENVIMA","Lenvima"],"phase":"phase_3","status":"active","brandName":"Lenvatinib Capsules","genericName":"Lenvatinib Capsules","companyName":"National Cancer Institute, Naples","companyId":"national-cancer-institute-naples","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and other kinases to inhibit tumor angiogenesis and growth. Used for Radioiodine-refractory differentiated thyroid cancer, Unresectable hepatocellular carcinoma, Advanced renal cell carcinoma (in combination with pembrolizumab).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}